Human plasminogen acknowledged as Orphan Drug
The European Commission, following the positive opinion of the European Medicines Agency (EMEA), has granted the designation of orphan drug to Human Plasminogen, made by Kedrion, in the form of eye drops used for the treatment of ligneous conjunctivitis. Ligneous conjunctivitis is a rare form of conjunctivitis which may lead to blindness and is characterized
EMAS registration for Kedrion: the company’s environmental policy reinforced
Kedrion SpA, specialized in the production of plasma–derived products, is one of the five Italian pharmaceutical companies which got EMAS registration. The company has joined an “Environmental Programme” and has thereby assumed specific environmental policy commitments. At the same time, it has drawn up an “Environmental Statement” which – in terms of regulation CE 761/2001
Research project for developing a new plasma derivative for the treatment of Hepatitis C
For the first time in Europe, a project is currently underway in Naples to develop an anti-infective product for Hepatitis C, containing neutralising immunoglobulins directed against specific viral antigens. With the western market estimated at $400 million ($200 million in the United States alone and about $40 million in Italy), it should guarantee a better
New plant in the Kedrion factory: 7 million invested and a 50% increase in production of Factor VIII and Factor IX
The new production department for sterile “Filling and Freeze-Drying of Heat-treated Coagulation Factors” in the Kedrion factory in Bolognana is now in operation. 7 million euros invested and a forecast increase of 50% in the production of Factor VIII and Factor IX which currently represent the 20% of turnover and the asset for the Contract
Nabi Biopharmaceuticals secures agreement with Kedrion to co-develop and commercialize CIVACIR® in Europe
Nabi Biopharmaceuticals (Nasdaq: NABI – News) announced that it has secured an agreement with Kedrion S.p.A., a global biopharmaceutical company, located in Lucca, Italy. Under the terms of the agreement, Nabi Biopharmaceuticals and Kedrion will pursue a common strategy to develop and commercialize Civacir® [Hepatitis C Immune Globulin (Human)] in Europe and the U.S., with
Kedrion and ProMetic form strategic alliance to develop Orphan Drugs from plasma
Kedrion S.p.A. and ProMetic BioTherapeutics, Inc., a subsidiary of ProMetic Life Sciences Inc. (TSX: PLI) (“ProMetic”) have formed a strategic alliance to develop orphan drugs derived from human plasma utilizing ProMetic’s proprietary manufacturing process, the Plasma Protein Purification System (PPPS). The alliance between the two companies was created to select specific proteins which can be
Kedrion and Nabi Biopharmaceuticals announce initiation of Civacir® phase II “proof-of-concept” clinical trial
Nabi (a biopharmaceutical company based in Florida) announced today that it has initiated in the USA, further to the agreement signed with Kedrion, its Phase II “proof-of-concept” clinical trial for Civacir® [epatitis C human immune globulin]. Civacir®, when approved, would be the first therapy for the prevention of the recurrence of hepatitis C-related liver disease
Plasma system, exporting the Italian “Contract Manufacturing” model to Chile
“Teamwork to improve plasma quality in Chile” is based on an agreement made in November 2005 by the Ministry of Health in Chile and SIMTI (Italian Transfusion Medicine and Immunohaematology Company), which marked the operational meeting between the Chilean delegation specially flown in to Italy and the CNR (National Research Council), SIMTI, Tuscany’s CRCC (Regional
Plasma derivates: reinforcing Tuscany as leader in the Balkans
Kedrion Biopharmaceuticals has won a contract to supply FIX in Bosnia. This is the plasma-derived drug used in the treatment of Haemophilia B (incidence of 1 in 60,000 people) which has a world market worth 200 million US dollars, with production of 430 million international units and distribution of 42% in Europe, 24% in North
“Von Willebrand Disease”: simple handbook for haemophilia centres, patients and their families
Answers to the questions most frequently asked by patients about causes, symptoms and treatments. A personal card that we recommend you to carry with you at all times. A monthly diary with annual summary. “Von Willebrand Disease – complex but not complicated (if you know about it)” is the title of the handbook which has